Medical Marijuana Market Analysis, Scope, and Growth by 2028
Medical Marijuana Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 11.71 Billion |
| Market Size by 2028 | US$ 40.03 Billion |
| Global CAGR (2021 - 2028) | 19.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
In November 2021, VIVO Cannabis Inc. launched its newest medical cannabis product formulation: high-dose cannabidiol (CBD) oil under its Beacon Medical brand. The entire family of Beacon Medical oil products are formulated using a non-GMO, food-grade medium-chain triglycerides (MCT) carrier oil which results in the final product being both scentless and flavourless in taste. VIVO simultaneously launched a Pediatric Compassionate Care Program to support caregivers and families requiring medical cannabis to treat a variety of pediatric conditions.
In November 2020, Panaxia Global Israeli subsidiary, Panaxia Labs Israel Ltd. (Panaxia Israel) completed the registration process and receipt of final regulatory approval from the health authorities in Germany, Europe's largest and fastest-growing cannabis market, for the marketing and distribution of a line of medical cannabis premium products. The products would be marketed in Germany under the brand name, Naxiva-Panaxol.
In September 2020, Emerald Health Therapeutics, Inc. and STENOCARE A/S received special approval from the Swedish Medicines Agency to provide medical cannabis oil to Swedish patients who have applied via their doctor to use such products for treatment purposes. Under an agreement signed in November 2019, Emerald supply STENOCARE with its medical cannabis products for Denmark and other markets such as Sweden. Together with the Swedish authorities, the companies are now processing the required information to commence import and distribution in Sweden.
Get Free Sample For